NeuroScienfitic Biopharmaceuticals (ASX: NSB) Webcast Replay
NeuroScienfitic Biopharmaceuticals Ltd (ASX: NSB) is a drug development company focused on developing novel peptide-based pharmaceutical drugs for the treatment of neurodegenerative conditions with high unmet medical need.
As a part of our ‘Meet the CEOs’ series, CEO Matthew Liddelow provides valuable insights to the company, its key markets and industry, and future prospects.
Recorded on 10th June 2020 at 12pm (AEST).
Join the next Meet the CEOs webcastFEATURE SPEAKERS
Matthew Liddelow
CEO & Managing Director
NeuroScienfitic Biopharmaceuticals Ltd (ASX: NSB) is a drug development company focused on developing novel peptide-based pharmaceutical drugs for the treatment of neurodegenerative conditions with high unmet medical need. NSB’s lead drug candidate, called EmtinB, is currently being developed as a treatment for neurodegenerative dementia and Alzheimer’s disease, and degenerative conditions of the optic nerve. EmtinB is in the advanced preclinicalphase of development with clinical development set to start by the end of 2020.
